Entrada Therapeutics

Go sign green light
Biotech

Entrada's 2-year ordeal ends as FDA lifts hold on DMD drug

Entrada is finally able to get its Duchenne muscular dystrophy candidate back on track after the FDA lifted a more than two-year-long hold.
James Waldron Feb 24, 2025 11:08am
visual of a parachute

Acadia brings BMS vet on board as CEO—Chutes & Ladders

Sep 27, 2024 8:30am
FDA stop sign

FDA rebuffs Entrada's attempt to get DMD clinical hold lifted

Nov 22, 2023 9:25am
image of a few paragliders

Amarin CEO abruptly resigns—Chutes & Ladders

Apr 7, 2023 9:30am
FDA

Fresh from Vertex payday, Entrada's DMD plans derailed by FDA

Dec 20, 2022 8:45am
Vertex

Vertex pays Entrada $224M for preclinical rare disease drug

Dec 8, 2022 9:06am